The eXoZymes platform removes this constraint entirely. Using AI-enhanced enzymes – exozymes - and a cell-free production platform, we have designed an exozyme cascade that convert simple feedstocks directly into NCT with engineering-level control.

Within months, NCT moved from concept to gram-scale production, achieving high conversion efficiency and consistent, pharma-grade purity. The process yields a single molecular species, avoiding the by-products and variability that complicate regulatory review and industrial scale-up.

Pure, scalable NCT enables a new category of metabolic health products grounded in cellular performance rather than symptomatic relief. This is not an incremental supplement improvement — it is category creation enabled by manufacturability.

Commercialization follows a deliberately capital-light model, combining direct-to-consumer branded products, ingredient supply to established wellness brands, and selective white-label partnerships. This structure accelerates revenue generation while preserving long-term platform value and pharmaceutical optionality.